注：1、本报告期初数同法定披露的上年年末数。 证券代码：688176 证券简称：亚虹医药 公告编号：2026-005 江苏亚虹医药科技股份有限公司 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载 2025 年度主要财务数据为初步核算数据，未经会计师事务所审 计，具体数据以江苏亚虹医药科技股份有限公司（以下简称"公司"）2025 年年 度报告为准，提请投资者注意投资风险。 | | | | 单位：人民币万元 | | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期 | 增减变动幅度（%） | | 营业总收入 | 27,712.15 | 20,156.24 | 37.49 | | 营业利润 | -43,130.08 | -38,380.59 | 不适用 | | 利润总额 | -43,636.32 | -38,679.58 | 不适用 | | 归属于母公司所有者的净利润 | -41,934.08 | -38,406.34 | 不适用 | | 归属于母公司所 ...

Core Viewpoint - The company, Yahuang Pharmaceutical, has received notification from the European Medicines Agency (EMA) regarding the acceptance of its marketing authorization application for product APL-1702 (CEVIRA) intended for the treatment of high-grade squamous intraepithelial lesions (HSIL) in patients [1] Group 1 - The marketing authorization application for APL-1702 has been accepted by the EMA, indicating a step forward in the regulatory process [1] - Following the acceptance, the product must still undergo further review and approval stages, introducing uncertainty regarding its successful market launch and specific timing [1] - Even if approved, there remains uncertainty about the product's ability to achieve commercial objectives [1] Group 2 - The acceptance of the marketing authorization application is not expected to have a significant impact on the company's recent performance [1]

中国经济网北京2月27日讯 亚虹医药（688176.SH）近期发布2025年年度业绩预亏公告。经财务部门初步测算，预计2025年度实现归 属于母公司所有者的净利润为-37,766.54万元到-45,319.85万元，与上年同期相比，净利润增加-6,913.51万元（亏损同比增长18.00%）到 639.80万元（亏损同比减少1.67%）。 亚虹医药上市首日开盘即破发，当日盘中最高价报20.00元，为上市以来最高价。 亚虹医药首次公开发行股票募集资金总额为25.28亿元，扣除发行费用后募集资金净额为23.81亿元。亚虹医药最终募集资金净额比原 计划多3.11亿元。亚虹医药于2021年12月31日披露的招股说明书显示，该公司拟募集资金20.70亿元，拟分别用于药品、医疗器械及配套 用乳膏生产项目，新药研发项目，营销网络建设项目，补充流动资金。 亚虹医药首次公开发行股票的费用总额为1.47亿元，其中中信证券获得承销费及保荐费1.30亿元。 亚虹医药的控股股东、实际控制人、董事长兼总经理是PANKE，美国国籍。 预计公司2025年度归属于母公司所有者扣除非经常性损益后的净利润为-39,628.87万元到-47,554 ...

（文章来源：证券日报） 证券日报网讯 2月13日，亚虹医药在互动平台回答投资者提问时表示，公司蓝光膀胱镜合作伙伴 R.WOLF的蓝光膀胱镜系统SYSTEMBLUE目前处于上市审评审批阶段。 ...

Group 1 - The stock price of Yahuang Pharmaceutical-U has shown a downward trend over the past week, with a cumulative decline of 2.67% and a fluctuation of 2.99% [1] - On February 12, the closing price was 12.05 yuan, reflecting a daily decrease of 0.50% [1] - The total trading volume over the past week was approximately 398 million yuan, with an active turnover rate of 1.01% on February 12 [1] Group 2 - The company announced a projected net loss for 2025, with a potential year-on-year increase in losses of 18.00% or a decrease of 1.67% [2] - Expected operating revenue for 2025 is projected to grow by 20.30% to 4.436 billion yuan [2] - Research and development expenses are expected to decrease, with significant progress reported in clinical trials for bladder cancer and ulcerative colitis treatments [2] Group 3 - All institutions have given buy or hold ratings based on data from November and September 2025, indicating a 100% consensus [3] - There have been no significant changes in public sentiment or updates on institutional research and target price information [3]

（文章来源：证券日报） 证券日报网讯 1月30日，亚虹医药发布公告称，公司预计2025年度实现营业收入约24，248.13万元到 29，097.76万元，同比增长20.30%到44.36%；归属于母公司所有者的净利润为-37，766.54万元到-45， 319.85万元。 ...

Core Viewpoint - Jiangsu Yahon Pharmaceutical Technology Co., Ltd. expects a significant net loss for the fiscal year 2025, with projections indicating a loss between 377.67 million yuan and 453.20 million yuan, reflecting an increase in losses compared to the previous year [2][3]. Financial Performance Forecast - The company anticipates a net profit attributable to shareholders of the parent company for 2025 to be between -377.67 million yuan and -453.20 million yuan, representing a year-on-year increase in losses of 18.00% to a decrease of 1.67% [2][3]. - The expected net profit after deducting non-recurring gains and losses is projected to be between -396.29 million yuan and -475.55 million yuan, with a year-on-year increase in losses of 16.28% to a decrease of 3.10% [2][3]. - Estimated operating revenue for 2025 is projected to be between 242.48 million yuan and 290.98 million yuan, indicating a year-on-year increase of 20.30% to 44.36% [3]. - Research and development expenses are expected to be between 253.67 million yuan and 304.40 million yuan, reflecting a decrease of 2.41% to 18.67% compared to the previous year [3]. Previous Year Performance - In 2024, the company reported a total profit of -386.80 million yuan, with a net profit attributable to shareholders of the parent company at -384.06 million yuan and a net profit after deducting non-recurring gains and losses at -408.95 million yuan [5]. Business Development and R&D Progress - The company's revenue primarily comes from the sales of Pazopanib tablets and Neralitinib tablets, with steady growth in sales and volume expected for 2025 [6]. - The company has made significant progress in multiple product developments, including the APL-1702 clinical trial results being presented at an international conference and the acceleration of its market approval process [7]. - APL-2401, a first-class innovative drug, received approval for clinical trials, demonstrating compliance with international standards and benefiting from expedited review processes [8]. - The company is also developing a portable disposable blue light bladder endoscope, APLD-2304, aimed at improving bladder cancer detection rates and patient comfort [8]. - Positive preliminary results were reported for APL-1401 in treating moderate to severe active ulcerative colitis, with plans for further evaluation in larger patient groups [9].

Financial Projections - The company expects a net profit attributable to shareholders of the parent company for 2025 to be between -377.67 million yuan and -453.20 million yuan, representing a year-on-year increase in losses of 18.00% to a decrease of 1.67%[3]. - The projected operating revenue for 2025 is approximately 242.48 million yuan to 290.98 million yuan, an increase of 20.30% to 44.36% compared to the previous year[3]. - The company’s total profit for 2024 was -386.80 million yuan, with a net profit attributable to shareholders of -384.06 million yuan[6]. - The company’s non-recurring gains and losses have decreased year-on-year, positively impacting the net profit attributable to shareholders[7]. - The financial data provided is preliminary and subject to final audit in the 2025 annual report[11]. Research and Development - Research and development expenses are expected to be between 253.67 million yuan and 304.40 million yuan, a decrease of 2.41% to 18.67% year-on-year[5]. - The company achieved significant progress in the development of multiple products, including APL-1702, which has been selected for presentation at the 2025 International Photodynamic Conference[7]. - APL-2302 has received approvals from both the FDA and NMPA for clinical trials, with the first subject enrolled in March 2025[8]. - The company’s APLD-2304, a portable disposable blue light bladder endoscope, has had its registration application accepted by the EU notified body, aimed at improving bladder cancer detection rates[9]. - APL-1401 for treating moderate to severe active ulcerative colitis has shown positive preliminary results in a Phase Ib clinical trial, with plans for further evaluation in a larger patient group[9].

| 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入(元) | | 游资净占比 散户净流入(元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 600276 恒瑞医药 | | 3.33 Z | 5.10% | -2.89 Z | -4.43% | -4421.19万 | -0.68% | | 000963 华东医药 | | 1.15 Z | 16.50% | -7275.41万 | -10.40% | -4271.00万 | -6.10% | | 000813 德展健康 | | 1.02亿 | 50.51% | -6009.16万 | -29.70% | -4212.39万 | -20.82% | | 300436 | 广生堂 | 1.01亿 | 5.29% | -2204.37万 | -1.16% | -7860.17万 | -4.13% | | 688382 益方生物 | | 3813.99万 | 13.10% | -337.73万 | -1.16% | -3476.26万 | -11.94% | | 600 ...

Core Viewpoint - Yahui Pharmaceutical (688176.SH) is currently trading at 13.15 yuan, reflecting a decline of 7.91%, and is in a state of share price decline since its IPO [1] Group 1: IPO Details - Yahui Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on January 7, 2022, with an issuance of 110 million shares at a price of 22.98 yuan per share [1] - The stock price fell below the IPO price on the first trading day, reaching a maximum of 20.00 yuan, which was the highest price since its listing [1] - The total funds raised from the IPO amounted to 2.528 billion yuan, with a net amount of 2.381 billion yuan after deducting issuance costs, exceeding the original plan by 311 million yuan [1] Group 2: Fund Utilization - The funds raised are intended for projects including drug and medical device production, new drug research and development, marketing network construction, and working capital supplementation [1] Group 3: Underwriting and Fees - The total cost of the IPO was 147 million yuan, with CITIC Securities receiving 130 million yuan as underwriting and sponsorship fees [1]